{"id":6728,"date":"2025-06-06T17:23:54","date_gmt":"2025-06-06T11:53:54","guid":{"rendered":"https:\/\/www.edhacare.com\/blogs\/?p=6728"},"modified":"2025-08-26T14:17:50","modified_gmt":"2025-08-26T08:47:50","slug":"latest-advancements-in-blood-cancer-treatment","status":"publish","type":"post","link":"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/","title":{"rendered":"Latest Advancements in Blood Cancer Treatment (2025 Update)","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Blood cancer is a broad term referring to various malignancies involving the blood, bone marrow, and lymph system. There are three prevalent types: leukemia, lymphoma, and multiple myeloma. Although each of these diseases differs in the manner they arise and progress, the one thing they have in common is that they interfere with the body&#8217;s capacity to combat infection, generate healthy blood cells, and sustain immune function.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In the last few decades, we have witnessed massive advancements in treatment. But 2025 is proving to be a turning point year. Thanks to innovative research, frontier therapies, and customized medicine, we are now seeing revolutionary advancements in how blood cancer gets diagnosed, treated, and even prevented from coming back.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This blog discusses the latest advancements in blood cancer treatment to keep patients, caregivers, and clinicians up-to-date with the treatments that will form the future.<\/span><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_74 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #2878bf;color:#2878bf\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #2878bf;color:#2878bf\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#why_staying_updated_matters_in_blood_cancer_treatment\" >Why Staying Updated Matters in Blood Cancer Treatment?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#types_of_blood_cancer_covered_in_this_blog\" >Types of Blood Cancer Covered in This Blog<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#leukemia\" >Leukemia<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#lymphoma\" >Lymphoma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#multiple_myeloma\" >Multiple Myeloma<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#latest_advancements_in_blood_cancer_treatment\" >Latest Advancements in Blood Cancer Treatment<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#car_t-cell_therapy_20\" >CAR T-Cell Therapy 2.0<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#bispecific_antibodies\" >Bispecific Antibodies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#next-generation_targeted_therapy\" >Next-Generation Targeted Therapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#immunomodulatory_drugs_imids_and_beyond\" >Immunomodulatory Drugs (IMiDs) and Beyond<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#gene_editing_crispr-based_research\" >Gene Editing &amp; CRISPR-Based Research<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#minimal_residual_disease_mrd_monitoring_technology\" >Minimal Residual Disease (MRD) Monitoring Technology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#ai_precision_medicine\" >AI &amp; Precision Medicine<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#clinical_trials_to_watch_in_2025\" >Clinical Trials to Watch in 2025<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#effect_of_these_developments_on_patient_results\" >Effect of These Developments on Patient Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#are_these_treatments_widely_available_yet\" >Are These Treatments Widely Available Yet?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#united_states_europe\" >United States &amp; Europe<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#india_other_countries\" >India &amp; Other Countries<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#medical_tourism\" >Medical Tourism<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#conclusion\" >Conclusion<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"why_staying_updated_matters_in_blood_cancer_treatment\"><\/span><span style=\"font-weight: 400;\">Why Staying Updated Matters in Blood Cancer Treatment?<\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">When it comes to <\/span><a href=\"https:\/\/www.edhacare.com\/treatments\/cancer\/blood\"><span style=\"font-weight: 400;\">blood cancer<\/span><\/a><span style=\"font-weight: 400;\">, timing and knowledge are everything. Medical science is advancing faster than ever. What was cutting-edge five years ago is now routine. And what seemed impossible just a few years back is now available in some of the world\u2019s top hospitals.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Here&#8217;s why staying updated is crucial:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><b>Reducing side effects:<\/b><span style=\"font-weight: 400;\"> More recent treatments have fewer and less intense side effects than conventional chemotherapy or radiation.<\/span><\/li>\n<li style=\"font-weight: 400;\"><b>Enhancing outlook:<\/b><span style=\"font-weight: 400;\"> Certain newer treatments dramatically improve survival and minimize the chance of recurrence.<\/span><\/li>\n<li style=\"font-weight: 400;\"><b>Targeted treatments:<\/b><span style=\"font-weight: 400;\"> New diagnostic technologies now enable physicians to customize treatment according to your particular type of cancer and genetic makeup.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">As a patient, you are better able to make informed choices. As a caregiver, you will be more involved and aware.<\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"types_of_blood_cancer_covered_in_this_blog\"><\/span><span style=\"font-weight: 400;\">Types of Blood Cancer Covered in This Blog<\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Let&#8217;s briefly mention the primary blood cancer types this blog will be discussing:<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"leukemia\"><\/span><span style=\"font-weight: 400;\">Leukemia<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">This cancer originates in the bone marrow and causes excessive production of abnormal white blood cells (WBCs). It includes acute and chronic types like AML (acute myeloid leukemia) and CLL (chronic lymphocytic leukemia).<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"lymphoma\"><\/span><span style=\"font-weight: 400;\">Lymphoma<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Lymphoma is a cancer that impacts the lymphatic system. It exists in two principal forms:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Hodgkin lymphoma (HL): Characterized by the presence of Reed-Sternberg cells.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Non-Hodgkin lymphoma (NHL): A heterogeneous group with numerous subtypes.<\/span><\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"multiple_myeloma\"><\/span><span style=\"font-weight: 400;\">Multiple Myeloma<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">It is a cancer of plasma cells, which are responsible for producing antibodies. It mostly occurs in older people and is characterized by causing bone damage and kidney problems.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Each type responds differently to treatment, and the 2025 advancements address these nuances in exciting ways.<\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"latest_advancements_in_blood_cancer_treatment\"><\/span><span style=\"font-weight: 400;\">Latest Advancements in Blood Cancer Treatment<\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Let&#8217;s immerse ourselves in the most thrilling breakthroughs that are transforming the treatment landscape in 2025.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"car_t-cell_therapy_20\"><\/span><span style=\"font-weight: 400;\">CAR T-Cell Therapy 2.0<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><a href=\"https:\/\/www.edhacare.com\/treatments\/cancer\/car-t-cell-therapy\"><span style=\"font-weight: 400;\">CAR T-cell therapy<\/span><\/a><span style=\"font-weight: 400;\"> is not new, but 2025 introduces us to a much more advanced version of this revolutionary treatment.<\/span><\/p>\n<p><b>What&#8217;s new?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Researchers have developed second-generation CAR T-cells that have improved safety profiles and reduced side effects such as cytokine release syndrome.<\/span><\/p>\n<p><b>Expanded approvals:<\/b><\/p>\n<p><span style=\"font-weight: 400;\">New CAR T-cell therapies have been FDA- and EMA-approved in 2025 for previously incurable subtypes of lymphoma and leukemia, particularly relapsed\/refractory disease.<\/span><\/p>\n<p><b>What does it mean for patients?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Patients who have exhausted all alternatives can now avail themselves of tailored immunotherapy with curative promise.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"bispecific_antibodies\"><\/span><span style=\"font-weight: 400;\">Bispecific Antibodies<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">These new-generation medicines are able to bind simultaneously to two distinct targets\u2014a cancer cell and a T-cell.<\/span><\/p>\n<p><b>How do they work?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Bispecific antibodies take cancer-killing T-cells directly to tumor cells, increasing the immune response.<\/span><\/p>\n<p><b>Big news in 2025:<\/b><\/p>\n<p><span style=\"font-weight: 400;\">A number of new bispecific antibodies have been approved this year for the treatment of non-Hodgkin lymphoma and Multiple Myeloma.<\/span><\/p>\n<p><b>Why does it matter?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">They are less toxic than standard chemotherapy and can be given in outpatient settings, so treatment is more convenient and less impactful.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"next-generation_targeted_therapy\"><\/span><span style=\"font-weight: 400;\">Next-Generation Targeted Therapy<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Targeted therapy continues to evolve. 2025 sees remarkable progress in inhibitors tailored to genetic mutations in blood cancers.<\/span><\/p>\n<p><b>Key updates<\/b><span style=\"font-weight: 400;\">:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><b>FLT3 inhibitors<\/b><span style=\"font-weight: 400;\"> for AML with FLT3 mutations.<\/span><\/li>\n<li style=\"font-weight: 400;\"><b>IDH1\/2 inhibitors<\/b><span style=\"font-weight: 400;\"> now with extended survival data.<\/span><\/li>\n<li style=\"font-weight: 400;\"><b>BTK inhibitors<\/b><span style=\"font-weight: 400;\"> offer better outcomes for CLL and mantle cell lymphoma.<\/span><\/li>\n<\/ul>\n<p><b>What&#8217;s new this year?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">A number of newly launched drugs are reporting improved response rates and less relapse in early clinical trials. These treatments are prescribed according to genetic markers, so they are far more targeted.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"immunomodulatory_drugs_imids_and_beyond\"><\/span><span style=\"font-weight: 400;\">Immunomodulatory Drugs (IMiDs) and Beyond<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">IMiDs have been the workhorse for multiple myeloma, and in 2025, we will also witness a new generation making its entry.<\/span><\/p>\n<p><b>Recent advances:<\/b><\/p>\n<p><span style=\"font-weight: 400;\">These new agents provide better tolerability, reduced toxicity, and enhanced immune stimulation.<\/span><\/p>\n<p><b>Key candidate drugs:<\/b><\/p>\n<p><span style=\"font-weight: 400;\">CELMoDs (cereblon E3 ligase modulators) are currently in final-stage trials and promise benefits even for triple-class refractory patients.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"gene_editing_crispr-based_research\"><\/span><span style=\"font-weight: 400;\">Gene Editing &amp; CRISPR-Based Research<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Gene editing has finally transitioned out of the lab and into clinical use in 2025.<\/span><\/p>\n<p><b>What&#8217;s currently happening?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">There are a number of clinical trials looking into CRISPR-Cas9 to fix genetic mutations in leukemia patients. Early-phase data indicate enhanced safety, which is an opening into personalized gene therapy.<\/span><\/p>\n<p><b>Ethical concerns:<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Of course, this is accompanied by ethical and regulatory implications, particularly with regard to germline editing. But somatic gene editing (affecting only the patient, not future generations) is increasingly being accepted.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"minimal_residual_disease_mrd_monitoring_technology\"><\/span><span style=\"font-weight: 400;\">Minimal Residual Disease (MRD) Monitoring Technology<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Tracing microscopic remnants of cancer cells after treatment allows for early prediction of relapse.<\/span><\/p>\n<p><b>2025 update:<\/b><\/p>\n<p><span style=\"font-weight: 400;\">With the advent of new technologies like liquid biopsy and AI platforms, MRD can now be detected in real time with unprecedented accuracy.<\/span><\/p>\n<p><b>Benefits:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Aids in deciding whether a patient is really in remission<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Guides decision on whether to proceed, discontinue, or change treatment<\/span><\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"ai_precision_medicine\"><\/span><span style=\"font-weight: 400;\">AI &amp; Precision Medicine<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Artificial intelligence is changing the way physicians diagnose, treat, and follow up on blood cancer.<\/span><\/p>\n<p><b>New in 2025:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">AI algorithms now predict relapse risk in individual patients.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Machine learning tools match patients with the most effective therapies based on genetic and molecular data.<\/span><\/li>\n<\/ul>\n<p><b>Smarter treatment planning:<\/b><\/p>\n<p><span style=\"font-weight: 400;\">AI is making it easier to tailor regimens, avoid overtreatment, and manage side effects more proactively.<\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"clinical_trials_to_watch_in_2025\"><\/span><span style=\"font-weight: 400;\">Clinical Trials to Watch in 2025<\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">If you or a loved one are fighting blood cancer, clinical trials may be your lifeline. Here are some of the most promising studies on the horizon:<\/span><\/p>\n<ol>\n<li style=\"font-weight: 400;\"><b>ZUMA-23 trial: <\/b><span style=\"font-weight: 400;\">CAR T for first-line therapy in aggressive lymphoma.<\/span><\/li>\n<li style=\"font-weight: 400;\"><b>CRISPR-TX005:<\/b><span style=\"font-weight: 400;\"> Genetically editing T-cells in relapsed AML patients.<\/span><\/li>\n<li style=\"font-weight: 400;\"><b>BI 3720931 trial:<\/b><span style=\"font-weight: 400;\"> Bispecific antibody in relapsed\/refractory myeloma.<\/span><\/li>\n<\/ol>\n<p><span style=\"font-weight: 400;\">You can look for trials on sites such as<\/span><a href=\"https:\/\/clinicaltrials.gov\/\"> <span style=\"font-weight: 400;\">ClinicalTrials.gov<\/span><\/a><span style=\"font-weight: 400;\">, or ask your oncologist about local possibilities. Being a participant usually means free use of experimental drugs and regular medical attention.<\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"effect_of_these_developments_on_patient_results\"><\/span><span style=\"font-weight: 400;\">Effect of These Developments on Patient Results<\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">The advances we have witnessed in 2025 are not hypothetical; they are saving lives.<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><b>Increased remission rates:<\/b><span style=\"font-weight: 400;\"> A number of new therapies have resulted in complete remission rates of over 80% in clinical trials in some subtypes.<\/span><\/li>\n<li style=\"font-weight: 400;\"><b>Reduced hospital stays: <\/b><span style=\"font-weight: 400;\">Outpatient administration of therapies like bispecific antibodies reduces the need for long hospitalizations.<\/span><\/li>\n<li style=\"font-weight: 400;\"><b>Better relapse management: <\/b><span style=\"font-weight: 400;\">Real-time MRD monitoring and AI-based alerts make it easier to catch and treat relapse early.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">In short, patients are living longer, living better, and enjoying more treatment options than ever before.<\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"are_these_treatments_widely_available_yet\"><\/span><span style=\"font-weight: 400;\">Are These Treatments Widely Available Yet?<\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">These treatments are not available everywhere but we are getting there.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"united_states_europe\"><\/span><span style=\"font-weight: 400;\">United States &amp; Europe<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">The majority of such treatments are already on the approved or expanded access programs list in the US and EU. They are, however, extremely costly, and not all may be insurable.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"india_other_countries\"><\/span><span style=\"font-weight: 400;\">India &amp; Other Countries<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">India is rapidly closing the gap with affordable biosimilars, being included in international clinical trials, and access to the latest treatment through top-class hospitals. Access to CAR T-cell therapy and gene editing, though, remains restricted.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"medical_tourism\"><\/span><span style=\"font-weight: 400;\">Medical Tourism<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Patients from nations with fewer options are now traveling overseas to India, Turkey, or Thailand for high-tech care at a fraction of the cost.<\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"conclusion\"><\/span><span style=\"font-weight: 400;\">Conclusion<\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">2025 marked a new chapter in the treatment of blood cancers. From CAR T-cell therapy to CRISPR gene editing and precision medicine powered by AI, the landscape is changing more rapidly than ever before. It brings fresh hope, particularly for patients with relapsed or resistant cases.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">If you or your loved one is fighting blood cancer, the time is now to get educated, ask for second opinions, and discover individualized treatment options.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Ready to move forward?<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Speak with a hematologist or oncology specialist about the latest possibilities. And if advanced treatment isn&#8217;t offered in your area, don&#8217;t be afraid to look into going abroad for treatment. Consult <\/span><a href=\"http:\/\/edhacare.com\"><span style=\"font-weight: 400;\">EdhaCare<\/span><\/a><span style=\"font-weight: 400;\"> and get to know the future of blood cancer treatment which is full of promise.<\/span><\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"excerpt":{"rendered":"<p>Blood cancer is a broad term referring to various malignancies involving the blood, bone marrow, [&hellip;]<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":21,"featured_media":6729,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[595,600,14],"tags":[352,1424,768],"class_list":["post-6728","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-hematology","category-oncology","tag-blood-cancer","tag-blood-cancer-treatment","tag-cost-of-blood-cancer-treatment-in-india"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Latest Advancements in Blood Cancer Treatment<\/title>\n<meta name=\"description\" content=\"Explore the latest advancements in blood cancer treatment, including CAR T-cell therapy, bispecific antibodies, gene editing, and more.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Latest Advancements in Blood Cancer Treatment\" \/>\n<meta property=\"og:description\" content=\"Explore the latest advancements in blood cancer treatment, including CAR T-cell therapy, bispecific antibodies, gene editing, and more.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"HealthCare Blogs - Get Medical Updates with EdhaCare\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/EdhaCare\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-06T11:53:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-26T08:47:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.edhacare.com\/blogs\/wp-content\/uploads\/2025\/06\/Latest-Advancements-in-Blood-Cancer-Treatment.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nishu Negi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Latest Advancements in Blood Cancer Treatment\" \/>\n<meta name=\"twitter:description\" content=\"Explore the latest advancements in blood cancer treatment, including CAR T-cell therapy, bispecific antibodies, gene editing, and more.\" \/>\n<meta name=\"twitter:creator\" content=\"@edhacare\" \/>\n<meta name=\"twitter:site\" content=\"@edhacare\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nishu Negi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/\"},\"author\":{\"name\":\"Nishu Negi\",\"@id\":\"https:\/\/www.edhacare.com\/blogs\/#\/schema\/person\/e461c98adfe26ba8e589ca78adc028f0\"},\"headline\":\"Latest Advancements in Blood Cancer Treatment (2025 Update)\",\"datePublished\":\"2025-06-06T11:53:54+00:00\",\"dateModified\":\"2025-08-26T08:47:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/\"},\"wordCount\":1405,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.edhacare.com\/blogs\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.edhacare.com\/blogs\/wp-content\/uploads\/2025\/06\/Latest-Advancements-in-Blood-Cancer-Treatment.jpg\",\"keywords\":[\"blood cancer\",\"blood cancer treatment\",\"Cost of Blood Cancer Treatment in India\"],\"articleSection\":[\"Cancer\",\"Hematology\",\"Oncology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/\",\"url\":\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/\",\"name\":\"Latest Advancements in Blood Cancer Treatment\",\"isPartOf\":{\"@id\":\"https:\/\/www.edhacare.com\/blogs\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.edhacare.com\/blogs\/wp-content\/uploads\/2025\/06\/Latest-Advancements-in-Blood-Cancer-Treatment.jpg\",\"datePublished\":\"2025-06-06T11:53:54+00:00\",\"dateModified\":\"2025-08-26T08:47:50+00:00\",\"description\":\"Explore the latest advancements in blood cancer treatment, including CAR T-cell therapy, bispecific antibodies, gene editing, and more.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#primaryimage\",\"url\":\"https:\/\/www.edhacare.com\/blogs\/wp-content\/uploads\/2025\/06\/Latest-Advancements-in-Blood-Cancer-Treatment.jpg\",\"contentUrl\":\"https:\/\/www.edhacare.com\/blogs\/wp-content\/uploads\/2025\/06\/Latest-Advancements-in-Blood-Cancer-Treatment.jpg\",\"width\":1200,\"height\":800,\"caption\":\"blood cancer treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.edhacare.com\/blogs\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Latest Advancements in Blood Cancer Treatment (2025 Update)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.edhacare.com\/blogs\/#website\",\"url\":\"https:\/\/www.edhacare.com\/blogs\/\",\"name\":\"HealthCare Blogs - Get Medical Updates with EdhaCare\",\"description\":\"Get updates of health care blogs with EdhaCare latest facts of medical\",\"publisher\":{\"@id\":\"https:\/\/www.edhacare.com\/blogs\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.edhacare.com\/blogs\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.edhacare.com\/blogs\/#organization\",\"name\":\"EdhaCare\",\"url\":\"https:\/\/www.edhacare.com\/blogs\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.edhacare.com\/blogs\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.edhacare.com\/blogs\/wp-content\/uploads\/2022\/09\/idha-care-logo-blogs.png\",\"contentUrl\":\"https:\/\/www.edhacare.com\/blogs\/wp-content\/uploads\/2022\/09\/idha-care-logo-blogs.png\",\"width\":200,\"height\":75,\"caption\":\"EdhaCare\"},\"image\":{\"@id\":\"https:\/\/www.edhacare.com\/blogs\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/EdhaCare\",\"https:\/\/x.com\/edhacare\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.edhacare.com\/blogs\/#\/schema\/person\/e461c98adfe26ba8e589ca78adc028f0\",\"name\":\"Nishu Negi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.edhacare.com\/blogs\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/592e5b70ca21953858a2aca88094a23b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/592e5b70ca21953858a2aca88094a23b?s=96&d=mm&r=g\",\"caption\":\"Nishu Negi\"},\"url\":\"https:\/\/www.edhacare.com\/blogs\/author\/nishu_negi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Latest Advancements in Blood Cancer Treatment","description":"Explore the latest advancements in blood cancer treatment, including CAR T-cell therapy, bispecific antibodies, gene editing, and more.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Latest Advancements in Blood Cancer Treatment","og_description":"Explore the latest advancements in blood cancer treatment, including CAR T-cell therapy, bispecific antibodies, gene editing, and more.","og_url":"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/","og_site_name":"HealthCare Blogs - Get Medical Updates with EdhaCare","article_publisher":"https:\/\/www.facebook.com\/EdhaCare","article_published_time":"2025-06-06T11:53:54+00:00","article_modified_time":"2025-08-26T08:47:50+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/www.edhacare.com\/blogs\/wp-content\/uploads\/2025\/06\/Latest-Advancements-in-Blood-Cancer-Treatment.jpg","type":"image\/jpeg"}],"author":"Nishu Negi","twitter_card":"summary_large_image","twitter_title":"Latest Advancements in Blood Cancer Treatment","twitter_description":"Explore the latest advancements in blood cancer treatment, including CAR T-cell therapy, bispecific antibodies, gene editing, and more.","twitter_creator":"@edhacare","twitter_site":"@edhacare","twitter_misc":{"Written by":"Nishu Negi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#article","isPartOf":{"@id":"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/"},"author":{"name":"Nishu Negi","@id":"https:\/\/www.edhacare.com\/blogs\/#\/schema\/person\/e461c98adfe26ba8e589ca78adc028f0"},"headline":"Latest Advancements in Blood Cancer Treatment (2025 Update)","datePublished":"2025-06-06T11:53:54+00:00","dateModified":"2025-08-26T08:47:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/"},"wordCount":1405,"commentCount":0,"publisher":{"@id":"https:\/\/www.edhacare.com\/blogs\/#organization"},"image":{"@id":"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.edhacare.com\/blogs\/wp-content\/uploads\/2025\/06\/Latest-Advancements-in-Blood-Cancer-Treatment.jpg","keywords":["blood cancer","blood cancer treatment","Cost of Blood Cancer Treatment in India"],"articleSection":["Cancer","Hematology","Oncology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/","url":"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/","name":"Latest Advancements in Blood Cancer Treatment","isPartOf":{"@id":"https:\/\/www.edhacare.com\/blogs\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#primaryimage"},"image":{"@id":"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.edhacare.com\/blogs\/wp-content\/uploads\/2025\/06\/Latest-Advancements-in-Blood-Cancer-Treatment.jpg","datePublished":"2025-06-06T11:53:54+00:00","dateModified":"2025-08-26T08:47:50+00:00","description":"Explore the latest advancements in blood cancer treatment, including CAR T-cell therapy, bispecific antibodies, gene editing, and more.","breadcrumb":{"@id":"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#primaryimage","url":"https:\/\/www.edhacare.com\/blogs\/wp-content\/uploads\/2025\/06\/Latest-Advancements-in-Blood-Cancer-Treatment.jpg","contentUrl":"https:\/\/www.edhacare.com\/blogs\/wp-content\/uploads\/2025\/06\/Latest-Advancements-in-Blood-Cancer-Treatment.jpg","width":1200,"height":800,"caption":"blood cancer treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/www.edhacare.com\/blogs\/latest-advancements-in-blood-cancer-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.edhacare.com\/blogs\/"},{"@type":"ListItem","position":2,"name":"Latest Advancements in Blood Cancer Treatment (2025 Update)"}]},{"@type":"WebSite","@id":"https:\/\/www.edhacare.com\/blogs\/#website","url":"https:\/\/www.edhacare.com\/blogs\/","name":"HealthCare Blogs - Get Medical Updates with EdhaCare","description":"Get updates of health care blogs with EdhaCare latest facts of medical","publisher":{"@id":"https:\/\/www.edhacare.com\/blogs\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.edhacare.com\/blogs\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.edhacare.com\/blogs\/#organization","name":"EdhaCare","url":"https:\/\/www.edhacare.com\/blogs\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.edhacare.com\/blogs\/#\/schema\/logo\/image\/","url":"https:\/\/www.edhacare.com\/blogs\/wp-content\/uploads\/2022\/09\/idha-care-logo-blogs.png","contentUrl":"https:\/\/www.edhacare.com\/blogs\/wp-content\/uploads\/2022\/09\/idha-care-logo-blogs.png","width":200,"height":75,"caption":"EdhaCare"},"image":{"@id":"https:\/\/www.edhacare.com\/blogs\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/EdhaCare","https:\/\/x.com\/edhacare"]},{"@type":"Person","@id":"https:\/\/www.edhacare.com\/blogs\/#\/schema\/person\/e461c98adfe26ba8e589ca78adc028f0","name":"Nishu Negi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.edhacare.com\/blogs\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/592e5b70ca21953858a2aca88094a23b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/592e5b70ca21953858a2aca88094a23b?s=96&d=mm&r=g","caption":"Nishu Negi"},"url":"https:\/\/www.edhacare.com\/blogs\/author\/nishu_negi\/"}]}},"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/www.edhacare.com\/blogs\/wp-json\/wp\/v2\/posts\/6728","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.edhacare.com\/blogs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.edhacare.com\/blogs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.edhacare.com\/blogs\/wp-json\/wp\/v2\/users\/21"}],"replies":[{"embeddable":true,"href":"https:\/\/www.edhacare.com\/blogs\/wp-json\/wp\/v2\/comments?post=6728"}],"version-history":[{"count":2,"href":"https:\/\/www.edhacare.com\/blogs\/wp-json\/wp\/v2\/posts\/6728\/revisions"}],"predecessor-version":[{"id":6910,"href":"https:\/\/www.edhacare.com\/blogs\/wp-json\/wp\/v2\/posts\/6728\/revisions\/6910"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.edhacare.com\/blogs\/wp-json\/wp\/v2\/media\/6729"}],"wp:attachment":[{"href":"https:\/\/www.edhacare.com\/blogs\/wp-json\/wp\/v2\/media?parent=6728"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.edhacare.com\/blogs\/wp-json\/wp\/v2\/categories?post=6728"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.edhacare.com\/blogs\/wp-json\/wp\/v2\/tags?post=6728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}